Last reviewed · How we verify
NCT07286656
A Study of GensSci098 in Subjects With Graves' Disease
Phase 1 trial testing GenSci098 in Safety in 24 participants. Currently enrolling.
28 October 2026
Quick facts
| Lead sponsor | Changchun GeneScience Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 21 November 2025 |
| Primary completion | 28 October 2026 |
| Estimated completion | 18 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- GenSci098 — full drug profile →
Conditions studied
- Safety — all drugs for Safety →
- Tolerability — all drugs for Tolerability →
- GenSci098 — all drugs for GenSci098 →
- Graves Disease — all drugs for Graves Disease →
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Safety or Tolerability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07286656
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GenSci098
Trials testing the same drug.
- NCT06569758 — A Study of GenSci098 in Subjects With Active Thyroid Eye Disease · Phase 1 · recruiting
Other recruiting trials for Safety
Currently open trials in the same condition.
- NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
- NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
- NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
- NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting
- NCT07016802 — A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) · Phase 1 · recruiting
Other Changchun GeneScience Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07534176 — To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets . · Phase 1 · not yet recruiting
- NCT07476586 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of GenSci161 in Healthy Adult Participants · Phase 1 · not yet recruiting
- NCT07491289 — GS1-144 in Participants With Hepatic Impairment and Healthy Female · Phase 1 · not yet recruiting
- NCT07537231 — A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Fe · Phase 1 · not yet recruiting
- NCT07366866 — A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults. · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07286656 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changchun GeneScience Pharmaceutical Co., Ltd.
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07286656.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing